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ABSTRACT
Access to healthy or diseased human neural tissue is a daunting task and represents a barrier
for advancing our understanding about the cellular, genetic, and molecular mechanisms underly-
ing neurogenesis and neurodegeneration. Reprogramming of somatic cells to pluripotency by
transient expression of transcription factors was achieved a few years ago. Induced pluripotent
stem cells (iPSC) from both healthy individuals and patients suffering from debilitating, life-
threatening neurological diseases have been differentiated into several specific neuronal sub-
types. An alternative emerging approach is the direct conversion of somatic cells (i.e., fibro-
blasts, blood cells, or glial cells) into neuron-like cells. However, to what extent neuronal direct
conversion of diseased somatic cells can be achieved remains an open question. Optimization
of current expansion and differentiation approaches is highly demanded to increase the differ-
entiation efficiency of specific phenotypes of functional neurons from iPSCs or through somatic
cell direct conversion. The realization of the full potential of iPSCs relies on the ability to pre-
cisely modify specific genome sequences. Genome editing technologies including zinc finger
nucleases, transcription activator-like effector nucleases, and clustered regularly interspaced
short palindromic repeat/CAS9 RNA-guided nucleases have progressed very fast over the last
years. The combination of genome-editing strategies and patient-specific iPSC biology will offer
a unique platform for in vitro generation of diseased and corrected neural derivatives for per-
sonalized therapies, disease modeling and drug screening. STEM CELLS 2014;32:2811–2817
INDUCED PLURIPOTENCY
Pluripotency is defined by the ability to pro-
duce from a single undifferentiated cell type,
cell derivatives representing the three germ
layers: meso-, endo-, and ectoderm. Pluripo-
tent stem cells (PSCs) of human origin were
first isolated from teratocarcinomas, giving rise
to embryonal carcinoma cell lines [1]. This
property is expected to be present in cells giv-
ing rise to gametes during human develop-
ment and thus, pluripotent embryonic germ
cells were described in 1998 [2]. The most
widely used PSCs of mammalian origin are
mouse embryonic stem cells (ESCs), derived
from the inner cell mass of preimplantation
embryos at the blastocyst stage [3, 4]. Using a
similar approach, human ESCs (hESCs) were
isolated from embryos almost 2 decades later
[5]. During human development, germline cells
undergo meiosis to produce gametes. The
remaining cellular types are known as somatic
cells, and they do not contribute to reproduc-
tive tissues. Early work has shown that miss-
expression of MyoD can convert cell fate
between germ layers [6, 7]. Similarly, ectopic
expression of master lineage-specific transcrip-
tional regulators allows cells to change from
one blood lineage to another [8]. However, it
was not recognized until recently how rela-
tively easy is for a terminally differentiated
somatic cell to re-acquire pluripotency proper-
ties or change cell fate across germ layers.
Successful reprogramming of somatic cells
to a pluripotent state by transient expression
of four transcription factors (OCT4, SOX2,
KLF4, and c-MYC) was achieved for the first
time with mouse cells in 2006 [9] and with
human fibroblasts in 2007 [10, 11] using retro-
viral vectors. Many researchers have produced
induced pluripotent stem cells (iPSCs) by
expressing the Yamanaka factors through inte-
grative or nonintegrative methods. Among the
former, retroviral and lentiviral vectors are the
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most widely used [12]. Induced pluripotency requires endoge-
nous activation of a pluripotency-associated gene expression
signature and a concomitant silencing of ectopic reprogram-
ming factors. Genomic integration of these transgenes is ran-
dom and becomes epigenetically regulated so that their
residual expression after long-term culture due to a lack of
complete silencing may prevent subsequent differentiation
[13] and make iPSCs prone to genomic alterations [14]. The
most common nonintegrative methodologies include Sendai
virus (SeV) [15], mRNA [16], plasmid DNA [17], or introduc-
tion of the recombinant proteins into somatic cells [16]. Also,
small molecules [18] can substitute some reprogramming
genes. Interestingly, microRNAs (miR) [19, 20] can produce
iPSCs on their own, without the pluripotency reprogramming
genes. It is especially relevant the ability of miR-302 to con-
tribute to iPSCs generation, which is in line with the well-
established role of miR-302 as a key regulator of pluripotency
in hESCs [21–25].
However, the generation of iPSCs is still inefficient, yield-
ing a low proportion of reprogrammed cells [18]. Many small
molecules and epigenetic remodeling drugs have been
reported to increase iPSC efficiency [26]. However, how these
ectopic factors can make a somatic cell to travel back in
development and become pluripotent through epigenetic
reprogramming remains elusive. Cellular reprogramming is
assumed to be a stressful cellular process. In fact, during the
reprogramming process several genomic insults including cod-
ing mutations, insertions/deletions (indels), and chromosomal
rearrangements occur. This genomic instability may activate
the DNA damage response (DDR) which may in turn contrib-
ute to a selection of specific clones during reprogramming to
pluripotency [27–29]. Also, whether or not induced pluripo-
tency is a purely stochastic process remains controversial [30].
There are important regulators of this process, such as p53
[31–33] and Mbd3. Indeed, inhibition of Mbd3 allowed a
reprogramming efficiency of almost 100% [34]. Recently, dif-
ferences in cell cycle length allowed the identification of
rapid-cycling cells as responsible for the bulk of reprog-
rammed cells [35]. Together, although many technical and bio-
logical questions about the cellular, molecular, and epigenetic
mechanisms underlying reprogramming remain elusive, mak-
ing induced reprogramming an obscure and low efficient pro-
cess, human iPSCs (hiPSCs) have revolutionized biomedical
research opening up unprecedented avenues in developmen-
tal biology, drug screening, and disease modeling. Because
access to healthy or diseased human neural tissue is a chal-
lenge and limits our understanding on neurogenesis and neu-
rodegeneration, diseases affecting the central nervous system
might particularly benefit from iPSC biology.
NEURAL DIFFERENTIATION OF PSCS
Several protocols for neuronal differentiation of human PSCs,
including iPSCs, have been reported. Neural commitment of
PSCs can be achieved through formation of embryoid bodies
and treatment with retinoic acid, a neuroectoderm inducer, or
by pharmacological inhibition of transforming growth factor-b
and bone morphogenic protein pathways (dual SMAD inhibi-
tion). The resulting neural stem/progenitor cells can be
expanded either attached to a substrate or as floating neuro-
spheres to be further exposed to growth factors inducing spe-
cific neuronal subtypes (i.e., spinal motor, cerebellar,
dopaminergic, or cortical interneurons) [36–40] (Fig. 1). For
Figure 1. Scheme showing the different methods to produce neurons from a somatic non-neuronal cell. Neural differentiation from
human iPSCs requires neural inducers, such as formation of embryoid bodies combined with stimulation with retinoic acid or inhibition
of transforming growth factor-b and bone morphogenic proteins (dual SMAD inhibition), followed by expansion of neural stem/progeni-
tor cells in monolayer or neurosphere cultures. Alternatively, fibroblasts, cord blood cells, or astrocytes can be directly converted to neu-
rons, either in vitro or in vivo. Abbreviations: miRNAs, microRNAs; iPSC, induced pluripotent stem cell.
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instance, motor neuron differentiation of hESCs and hiPSCs
has been refined to a point that spinal lateral column pheno-
types can be obtained [36, 41]. Similarly, for dopaminergic
neurons, midbrain phenotypes can be successfully produced
in high yields from hESCs and hiPSCs [38, 39]. These human
PSC (hPSC)-derived neurons were transplanted in animal mod-
els of neurological disease where survived and contributed to
the partial recovery of several neurological parameters,
including behavior. These results should encourage us to fur-
ther explore hPSC-derived neurons in preclinical settings [42].
Beyond potential cell therapy applications, hPSC-derived neu-
rons open up new avenues in drug screening and disease
modeling applications.
Induced PSCs have been generated from biopsies of
patients harboring mutations associated to amyotrophic lat-
eral sclerosis [41], spinal muscular atrophy [43, 44], Parkinson
disease [45, 46], Alzheimer disease [47], and Rett syndrome
[48]. Some of these patient/disease-specific iPSCs give rise,
under proper inductive conditions, to the affected neuronal
subtype, opening up new avenues to explore: (a) the potential
of these neurons to graft the patient in an autologous setting,
provided the procedure is safe and effective, (b) the in vitro
neuronal differentiation of mutated iPSC as a disease model
to unravel the developmental, cellular, and molecular mecha-
nisms underlying the disease onset and progression, and (c)
large-scale drug screening aimed at restoring impaired func-
tions or preventing neuronal degeneration. In fact, long-term
culture of dopamine neurons differentiated from mutant Par-
kinson hiPSCs showed increased apoptosis and decreased
number and shorter neurites [45]. In another study, Parkinson
patient-specific iPSC were generated and differentiated into
neural derivatives that were challenged with mitochondrial
stressors, revealing an increased susceptibility as compared to
neural cells from control iPSCs. Furthermore, supplementation
of the culture medium with the antioxidant coenzyme Q10 or
rapamycin caused partial protection against neural degenera-
tion [49]. These studies underscore the potential of iPSCs and
iPSC-neural derivatives to gain insights into the underlying
mechanisms of neurodegeneration and to explore them as a
biological platform to screen potential therapeutic molecules,
eventually contributing to the development of novel pharma-
cological approaches.
Collections of patient/disease-specific hiPSCs, including
neurological conditions [50], will be of utmost value to
advance our understanding of the disease. Furthermore, an
initiative for public banking of diseased fibroblasts from
patients with mutations related to neurodegenerative diseases
is already ongoing [51]. It will be important to consider both
sporadic and familial forms of neurological diseases to allow
comparisons among patients and mutations in order to iden-
tify common and distinct mechanisms underlying the disease
pathogenesis as well as wide-acting drugs. However, the gen-
eration of functional neurons from hPSCs, namely cells that
express markers of neuronal differentiation (b-III tubulin,
microtubule associated protein-2, or NeuN), fire action poten-
tials, synthesize and release neurotransmitters and form syn-
apses with neighboring neurons, often requires extended
periods of culture and the available protocols are complex
and suffer from high variability. Recently, lineage priming to
neurons from hESCs and iPSCs was induced by forced expres-
sion of a single transcription factor (either NEUROGENIN-2 or
NEUROD1) which resulted in the emergence of mature neu-
rons within 2 weeks, speeding up significantly the time
required to obtain mature human neurons in vitro [52].
Besides differentiation efficiency, a homogeneous population
of lineage-specific cells (i.e., neuronal populations) from hPSCs
must be eventually obtained to prevent the presence in the
culture of residual undifferentiated cells which may exert
undesired/misleading effects both in vitro and in vivo.
DIRECT CONVERSION OF SOMATIC CELLS INTO NEURONS
After the seminal reprogramming work of Yamanaka and
coworkers, other investigators started testing the hypothesis
that expression of transcriptional regulators might act as neu-
ral cell determinants to non-neural differentiated somatic
cells. Indeed, ectopic expression of ASCL1, BRN2A, and MYT1L
turned fibroblasts directly (no pluripotent stage involved) into
induced neurons (iNs) [53, 54] (Fig. 1). Expression of addi-
tional neural lineage-specific transcriptional regulators further
promoted the conversion of human fibroblasts into dopamine
[55, 56] and motor neurons [57]. Interestingly, although this
direct conversion into iNs rarely requires the neural progeni-
tor state, human fibroblasts can also be induced by the sole
expression of SOX2 to become multipotent neural stem cells,
able to differentiate into neurons, astrocytes, and oligoden-
droglia [58]. Direct conversion of fibroblasts into iNs usually
requires a skin biopsy that is expanded in culture to generate
enough starting material. Therefore, the use of a more acces-
sible source in medical diagnostic procedures, such as blood,
would be highly advantageous. In fact, cord blood stem cells
have been recently reprogrammed into iNs by forced expres-
sion of SOX2 and c-MYC [59]. This work showed for the first
time that cells from mesodermal origin can be switched to an
ectodermal fate with only two transcription factors. The pro-
cedure for generating iNs relies on the use of integrative vec-
tors, and similar to the production of hiPSCs, is rather
complex and inefficient. Recently, some progress has been
made in direct reprogramming of non-human primate fibro-
blasts into region-specific neural progenitors through transient
expression of the four Yamanaka factors using nonintegrative
SeV in combination with specific neural culture conditions
[60]. These results represent an important technical progress
for the generation of iNs, although the presence of a pluripo-
tent intermediate cellular stage cannot be ruled out in these
experiments, and the process continues to be quite ineffi-
cient. Because SeV vectors seem to be one of the most effi-
cient nonintegrative strategies for reprogramming blood cells
to iPSCs [61, 62] it will be of interest to determine if delivery
of SOX2 and c-MYC by means of SeV transduction might
enhance the direct reprogramming efficiency of blood cells
into iNs. Blood-derived iNs could provide a unique tool for
drug screening and will facilitate the development of a cellu-
lar platform for the generation of patient-specific neuronal
cells for future biomedical applications.
Direct conversion of non-neuronal cells into neurons is
also possible in vivo. Human fibroblasts or astrocytes engi-
neered to express doxycycline-inducible ASCL1, BRN2A, and
MYT1L are converted into neurons within the rodent brain
after doxycycline addition. Interestingly, endogenous brain
astrocytes were also converted into iNs highlighting a specie-
Velasco, Salazar, Giorgetti et al. 2813
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independent direct conversion [63]. In a similar approach,
NeuroD1 transduction of reactive astrocytes and oligodendro-
cytes present after acute brain damage or as a consequence
of a chronic damage in a transgenic Alzheimer disease mouse
model also rendered iNs in vivo. Notably, astrocyte-derived
iNS mainly produced glutamatergic neurons whereas
oligodendrogyte-derived iNs generated both glutamatergic
and gabaergic neurons [64]. To what extent neuronal direct
conversion is possible in other diseased somatic non-neural
cells remains an open question. While these results are prom-
ising, the field has yet to clearly address how much these iNs
resemble to neurons/neural progenitors and whether iNs
retain epigenetic memory; that is, they retain gene expression
and epigenetic profiles similar to the donor cell type (fibro-
blasts, hematopoietic cells and astrocytes) that was originally
reprogrammed. This epigenetic memory is crucial since it may
influence subsequent differentiation potential. Taken together,
integration of technical and biological expertise gained from
hiPSCs and hiNs will boost our ability to move the field for-
ward facilitating the implementation of disease modeling and
drug screening applications. Eventually, the realization of the
full potential of iPSCs/iNs relies on the ability to improve the
reprogramming/direct conversion and combine efficient differ-
entiation protocols with the precise modification of specific
genome sequences.
TARGETED GENOME EDITING IN HUMAN IPSCS
hiPSCs are widely being used in developmental biology and
disease modeling. However, they are envisioned to become a
unique tool for disease-specific drug screening, and possibly, a
patient-specific cell replacement approach [65] (Fig. 2). How-
ever, the realization of the full potential of hiPSCs relies on
the ability to precisely modify/correct specific genome
sequences, with a prospect of personalized cell therapy.
Importantly, genome editing in hPSCs has evolved from being
a daunting task to a widely spread procedure in worldwide
laboratories. The reasons for this are twofold: (a) human PSCs
are especially amenable for genome editing since they can
undergo extensive culture manipulations, such as drug selec-
tion and clonal expansion, while still maintaining their pluripo-
tency and genome stability [66], and (b) genome editing
technology has progressed extremely rapid over the last few
years including zinc finger nucleases (ZFNs), transcription
activator-like effector nucleases (TALENs), clustered regularly
interspaced short palindromic repeat/CAS9 RNA-guided nucle-
ases (CRISPR/CAS9) (Table 1), and helper-dependent adenovi-
ral vectors (HDAdVs). An important aspect is that cells that
have undergone genome editing should contain only the
intended change in an otherwise isogenic background, thus
providing the most stringent test of gene function. However,
this may not be the case due to off-target effects of ZFNs,
TALENs, and CRISPR/CAS9. However, these genome-editing
tools are under continuous improvement [67, 68]. The biologi-
cal mechanisms underlying these genome-editing tools in
human PSCs cannot be covered in this review due to space
constrains, but they have been extensively and elegantly
reviewed elsewhere [66]. Table 1 summarizes the differential
biological and technical features of cutting-edge main
genome-editing approaches. Although only a minority of the
neurodegenerative diseases is caused by a specific identified
mutation, there are examples showing the potential of
genome editing in iPSC for neurological diseases.
Huntington disease is caused by expansion of a poly-
glutamine motif in HUNTINGTIN. Through homologous recom-
bination in iPSCs, the number of glutamines in this protein
was reduced, resulting in decreased apoptosis and improve-
ment in oxygen consumption rate in corrected neural progeni-
tors [69]. Spinal muscular atrophy is a genetic autosomal
recessive disease caused by mutations of the SMN1 gene
which results in a nonfunctional protein causing motor neuron
Figure 2. Cartoon depicting the strategy for combining genome editing and patient-specific human iPSCs (hiPSCs) for in vitro genera-
tion of diseased and corrected lineage-specific derivatives for disease modeling and drug screening. Studies on disease modeling and
drug screening should be undertaken in parallel on both diseased and genetically corrected cell lines. Due to the high variability existing
among hiPSC lines derived from distinct starting cells, using different methods, and from different genetic backgrounds, the use of an
isogenic mutation-corrected iPSC line is essential as a control. Abbreviations: CRISPR/CAS9, clustered regularly interspaced short palin-
dromic repeat/CAS9 RNA-guided nucleases; HDAdV, helper-dependent adenoviral vectors; iPSCs, induced pluripotent stem cells; TALENs,
transcription activator-like effector nucleases; ZFN, zinc finger nucleases.
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degeneration. As a compensatory mechanism, these patients
rely on the expression of SMN2, which is highly homologous to
SMN1 but has a change in a nucleotide that alters its splicing,
with a consequent reduction in the amount of SMN produced.
Using single-stranded DNA sequences, editing of the SMN2 was
performed, resulting in a SMN1-like protein that includes the
exon 7. This change was shown to be stable and correlated
with increased motor neuron survival in repaired cells [43].
Recently, ZFN-mediated genome editing and iPSC technology
were combined to generate sets of isogenic diseased and con-
trol hiPSCs that differ exclusively at either of two susceptibility
variants for Parkinson’s disease by modifying the underlying
point mutations in the a-synuclein gene [46]. In addition, a
point mutation related to familial Parkinson has been corrected
using HDAdVs. Notably, these diseased hiPSCs produced neural
stem cells that showed alterations in the nuclear architecture,
a finding that was not previously reported as related to this
pathology. Genetic correction of hiPSCs resulted in normaliza-
tion of the nuclear alterations, decreased susceptibility to apo-
ptosis, as well as increased neuronal production [70]. The
robust capability to genetically correct Parkinson disease-
causing point mutations in patient-derived hiPSCs represents a
noteworthy progress in basic neurosciences, and a significant
advance toward hiPSC-based cell replacement therapies and
drug testing. Whether or not the corrected neurons will survive
after transplantation in the altered central nervous system
(environment) represents a next level of complexity that still
needs to be addressed.
CONCLUSION
Over the last decade we have witnessed significant progress
in both our understanding of cell fate determinants and also
in the possibilities to use reprogramming in the preclinical
setting. The generation of human neurons by these methodol-
ogies will definitively allow the analysis of the mechanisms
causing familial and sporadic cases of neurological conditions.
Patients therefore can benefit from in vitro differentiated neu-
rons and specific drugs identified by high-throughput screen-
ing. If genome editing turns out to be safe and effective, we
envision a future prospective production of clinically relevant
neuronal types within the brain of affected people. Whether
or not the synaptic communication will be re-established
properly in the diseased brain is a different question, but
repopulation of the affected neuronal phenotype, either by
transplantation of differentiated neurons or by direct conver-
sion of resident glial cells is a very encouraging step forward.
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